Matches in SemOpenAlex for { <https://semopenalex.org/work/W2146249493> ?p ?o ?g. }
Showing items 1 to 95 of
95
with 100 items per page.
- W2146249493 endingPage "37" @default.
- W2146249493 startingPage "37" @default.
- W2146249493 abstract "Alzheimer’s disease (AD) is increasing in frequency as the global population ages. Five drugs are approved for treatment of AD, including four cholinesterase inhibitors and an N-methyl-D-aspartate (NMDA)-receptor antagonist. We have an urgent need to find new therapies for AD. We examined Clinicaltrials.gov, a public website that records ongoing clinical trials. We examined the decade of 2002 to 2012, to better understand AD-drug development. We reviewed trials by sponsor, sites, drug mechanism of action, duration, number of patients required, and rate of success in terms of advancement from one phase to the next. We also reviewed the current AD therapy pipeline. During the 2002 to 2012 observation period, 413 AD trials were performed: 124 Phase 1 trials, 206 Phase 2 trials, and 83 Phase 3 trials. Seventy-eight percent were sponsored by pharmaceutical companies. The United States of America (U.S.) remains the single world region with the greatest number of trials; cumulatively, more non-U.S. than U.S. trials are performed. The largest number of registered trials addressed symptomatic agents aimed at improving cognition (36.6%), followed by trials of disease-modifying small molecules (35.1%) and trials of disease-modifying immunotherapies (18%). The mean length of trials increases from Phase 2 to Phase 3, and the number of participants in trials increases between Phase 2 and Phase 3. Trials of disease-modifying agents are larger and longer than those for symptomatic agents. A very high attrition rate was found, with an overall success rate during the 2002 to 2012 period of 0.4% (99.6% failure). The Clinicaltrials.gov database demonstrates that relatively few clinical trials are undertaken for AD therapeutics, considering the magnitude of the problem. The success rate for advancing from one phase to another is low, and the number of compounds progressing to regulatory review is among the lowest found in any therapeutic area. The AD drug-development ecosystem requires support." @default.
- W2146249493 created "2016-06-24" @default.
- W2146249493 creator A5060050537 @default.
- W2146249493 creator A5060487287 @default.
- W2146249493 creator A5087278644 @default.
- W2146249493 date "2014-01-01" @default.
- W2146249493 modified "2023-10-12" @default.
- W2146249493 title "Alzheimer’s disease drug-development pipeline: few candidates, frequent failures" @default.
- W2146249493 cites W1974554585 @default.
- W2146249493 cites W1980821805 @default.
- W2146249493 cites W1983349802 @default.
- W2146249493 cites W1997362383 @default.
- W2146249493 cites W2004665143 @default.
- W2146249493 cites W2032698104 @default.
- W2146249493 cites W2034142305 @default.
- W2146249493 cites W2043583692 @default.
- W2146249493 cites W2054267384 @default.
- W2146249493 cites W2061286463 @default.
- W2146249493 cites W2061495286 @default.
- W2146249493 cites W2088343957 @default.
- W2146249493 cites W2092025391 @default.
- W2146249493 cites W2106096253 @default.
- W2146249493 cites W2109823050 @default.
- W2146249493 cites W2116211664 @default.
- W2146249493 cites W2129972383 @default.
- W2146249493 cites W2151585937 @default.
- W2146249493 cites W2166626010 @default.
- W2146249493 cites W2319447581 @default.
- W2146249493 cites W2325463191 @default.
- W2146249493 doi "https://doi.org/10.1186/alzrt269" @default.
- W2146249493 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4095696" @default.
- W2146249493 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25024750" @default.
- W2146249493 hasPublicationYear "2014" @default.
- W2146249493 type Work @default.
- W2146249493 sameAs 2146249493 @default.
- W2146249493 citedByCount "1324" @default.
- W2146249493 countsByYear W21462494932014 @default.
- W2146249493 countsByYear W21462494932015 @default.
- W2146249493 countsByYear W21462494932016 @default.
- W2146249493 countsByYear W21462494932017 @default.
- W2146249493 countsByYear W21462494932018 @default.
- W2146249493 countsByYear W21462494932019 @default.
- W2146249493 countsByYear W21462494932020 @default.
- W2146249493 countsByYear W21462494932021 @default.
- W2146249493 countsByYear W21462494932022 @default.
- W2146249493 countsByYear W21462494932023 @default.
- W2146249493 crossrefType "journal-article" @default.
- W2146249493 hasAuthorship W2146249493A5060050537 @default.
- W2146249493 hasAuthorship W2146249493A5060487287 @default.
- W2146249493 hasAuthorship W2146249493A5087278644 @default.
- W2146249493 hasBestOaLocation W21462494931 @default.
- W2146249493 hasConcept C126322002 @default.
- W2146249493 hasConcept C143998085 @default.
- W2146249493 hasConcept C2779134260 @default.
- W2146249493 hasConcept C2780035454 @default.
- W2146249493 hasConcept C2908647359 @default.
- W2146249493 hasConcept C535046627 @default.
- W2146249493 hasConcept C64903051 @default.
- W2146249493 hasConcept C71924100 @default.
- W2146249493 hasConcept C98274493 @default.
- W2146249493 hasConcept C99454951 @default.
- W2146249493 hasConceptScore W2146249493C126322002 @default.
- W2146249493 hasConceptScore W2146249493C143998085 @default.
- W2146249493 hasConceptScore W2146249493C2779134260 @default.
- W2146249493 hasConceptScore W2146249493C2780035454 @default.
- W2146249493 hasConceptScore W2146249493C2908647359 @default.
- W2146249493 hasConceptScore W2146249493C535046627 @default.
- W2146249493 hasConceptScore W2146249493C64903051 @default.
- W2146249493 hasConceptScore W2146249493C71924100 @default.
- W2146249493 hasConceptScore W2146249493C98274493 @default.
- W2146249493 hasConceptScore W2146249493C99454951 @default.
- W2146249493 hasIssue "4" @default.
- W2146249493 hasLocation W21462494931 @default.
- W2146249493 hasLocation W21462494932 @default.
- W2146249493 hasLocation W21462494933 @default.
- W2146249493 hasLocation W21462494934 @default.
- W2146249493 hasOpenAccess W2146249493 @default.
- W2146249493 hasPrimaryLocation W21462494931 @default.
- W2146249493 hasRelatedWork W1993324100 @default.
- W2146249493 hasRelatedWork W1994397669 @default.
- W2146249493 hasRelatedWork W2018942591 @default.
- W2146249493 hasRelatedWork W2065271792 @default.
- W2146249493 hasRelatedWork W2069539943 @default.
- W2146249493 hasRelatedWork W2096105485 @default.
- W2146249493 hasRelatedWork W2129267808 @default.
- W2146249493 hasRelatedWork W2255799423 @default.
- W2146249493 hasRelatedWork W2372770165 @default.
- W2146249493 hasRelatedWork W4323351292 @default.
- W2146249493 hasVolume "6" @default.
- W2146249493 isParatext "false" @default.
- W2146249493 isRetracted "false" @default.
- W2146249493 magId "2146249493" @default.
- W2146249493 workType "article" @default.